



Clinical evidence compendium

For managing recurrent pleural effusion or malignant ascites

A summary of the clinical evidence supporting the use of indwelling pleural and peritoneal catheter (IPC) systems



Dear Reader,

Every day, patients with recurrent pleural effusion or malignant ascites need drainage. This aims to relieve associated symptoms and to significantly enhance the patient's quality of life. Treatment should provide safe, effective management and avoid severe complications, such as infection, blockage and catheter failure.

Becton, Dickinson and Company (BD) is committed to continuing the advancement of palliative options for patients with pleural effusion and malignant ascites. Since 1997, the PleurX™ catheter system has offered compassionate care to more than 400,000 patients with pleural effusion and malignant ascites in over 50 countries. It has been studied in more than 50 clinical articles, and referenced in more than 35 peer-reviewed journal articles. The PleurX catheter system is a clinically proven solution to palliate this fragile patient population.

This summary was compiled to facilitate the reader in accessing the literature pertinent to the use of the indwelling pleural and peritoneal catheter (IPC) in both the pleural and peritoneal space. All studies in this compendium were found via a literature search and the summaries are provided as a courtesy to you, the reader.

All information in this summary was current as of September 26, 2017 and BD is not liable for any inaccuracies therein.



Table of contents

This compendium contains highlights from the clinical papers listed below.

Please contact your local BD representative should you require any more information or if you have any questions regarding the compendium or PleurX catheter.

Managing pleural effusion

Identification of clinical factors predicting PleurX catheter removal in patients treated for malignant pleural effusion (Warren WH, et al. <i>Eur J Cardiothorac Surg</i> 2008)	4–5
Single-center experience with 250 tunnelled pleural catheter insertions for malignant pleural effusion (Tremblay and Michaud. <i>CHEST</i> 2006)	6–7
Management of malignant pleural effusions using the PleurX catheter (Warren WH, et al. <i>Ann Thorac Surg</i> 2008)	8–9
Phase III intergroup study of talc poudrage vs talc slurry sclerosis for malignant pleural effusion (Dresler CM, et al. <i>CHEST</i> 2005)	10–11
Talc pleurodesis through indwelling pleural catheters for malignant pleural effusions: retrospective case series of a novel clinical pathway (Ahmed L, et al. <i>CHEST</i> 2014)	12–13
Indwelling tunneled pleural catheters for management of hepatic hydrothorax. A pilot study (Chen A, et al. <i>Ann Am Thorac Soc</i> 2016)	14–15
Management of malignant pleural effusion: a cost-utility analysis (Shafiq M, et al. <i>J Broncho Interv Pulmonol</i> 2015)	16–17

Managing malignant ascites

Prospective evaluation of the PleurX catheter when used to treat recurrent ascites associated with malignancy (Courtney A, et al. <i>J Vasc Interv Radiol</i> 2008)	18–19
Tunneled peritoneal drainage catheter placement for refractory ascites: single-center experience in 188 patients (Lungren MP, et al. <i>J Vasc Interv Radiol</i> 2013)	20–21
PleurX peritoneal catheter drainage system for vacuum-assisted drainage of treatment-resistant, recurrent malignant ascites: a NICE Medical Technology Guidance (White J and Carolan-Rees G. <i>Appl Health Econ Health Policy</i> 2012)	22–23

Identification of clinical factors predicting PleurX catheter removal in patients treated for malignant pleural effusion



Study author(s)

William H. Warren, Anthony W. Kim and Michael J. Liptay



Publication

Eur J Cardiothorac Surg 2008
DOI: 10.1016/j.ejcts.2007.10.002



Study design (level of evidence)

Case-controlled study



Study location

United States



Study objective

To identify the clinical predictors of catheter removability after spontaneous pleurodesis



Study length

8 years



Study protocol

- Retrospective review of patient records
- Patients were assigned to one of four groups based on primary neoplasm site
- Assessed clinical parameters' influence on catheter removability after spontaneous pleurodesis



Patient population

263 patients with malignant pleural effusion



Study limitations

- Sample sizes vary considerably between groups
- Study spanned 8 years – results do not account for refinements to the catheter insertion procedure



Study findings

59% of catheters (n=173) were removed after achieving spontaneous pleurodesis

- 70% spontaneous pleurodesis rate among patients with breast and gynaecological cancer

<2% infection rate **<4%** catheter blockage rate

29 days mean catheter indwelling time to achieve spontaneous pleurodesis

Predictors of catheter removability:

- breast or gynaecological cancer
- pleural fluid malignancy
- no trapped lung



Key points

Successful spontaneous pleurodesis resulted in catheter removal for most catheter insertions

PleurX catheters were extremely well tolerated with very low levels of infection and catheter blockage

Patients preferred to keep the catheter in than to risk fluid re-accumulation, emphasising its excellent tolerability

The catheter palliates patients with trapped lung or persistent pleural fluid accumulation, where alternative treatments are likely to fail



Study conclusions

PleurX catheters alleviate unpleasant symptoms of malignant pleural effusion, with few complications

Patients with malignant pleural effusion commonly achieve spontaneous pleurodesis with the PleurX catheter

Single-center experience with 250 tunnelled pleural catheter insertions for malignant pleural effusion



Study author(s)

Alain Tremblay and Gaëtane Michaud



Publication

CHEST 2006

DOI: 10.1378/chest.129.2.362



Study design (level of evidence)

Case-controlled study



Study location

Canada



Study objective

To describe the use of the PleurX catheter for managing dyspnoea in malignant pleural effusion in a large group of patients



Study length

3 years



Study protocol

- A monocentric, retrospective analysis of sequential tunnelled pleural catheter insertions
- All patients underwent tunnelled pleural catheter (PleurX) insertion



Patient population

223 patients with malignant pleural effusion



Study limitations

- Results need to be confirmed in a multicentric study
- Lack of symptom control studies makes comparing the research difficult



Study findings

96% symptom relief at 2-week follow-up

144 days median overall survival time after insertion

89% catheter insertions achieved symptom control (n=222)

- 39% achieved complete symptom control (n=97)
- 50% achieved partial symptom control (n=125)
- 4% achieved no symptom control (n=9)

4% of catheter insertion procedures failed (n=10)

43% insertions achieved spontaneous pleurodesis (n=103)

90% of successful insertions needed no repeat procedures

56 days mean catheter indwelling time

8% of patients had symptomatic loculations (n=21)

4% of patients had asymptomatic loculations (n=10)



Key points

Long-lasting spontaneous pleurodesis in most patients, repeat procedures were rarely required

The PleurX catheter successfully palliates malignant pleural effusion and facilitates outpatient management

Almost all patients reported symptom relief 2 weeks after insertion

Low rates of procedure failure, complications and infections



Study conclusions

Patients had an overall median catheter indwelling time of 144 days, with low complication rates

The PleurX catheter should be considered as first-line treatment for patients with symptomatic malignant pleural effusion and dyspnoea

Management of malignant pleural effusions using the PleurX catheter



Study author(s)

William H. Warren, Robert Kalimi,
Lisa M. Khodadadian and Anthony W. Kim



Publication

Ann Thorac Surg 2008
DOI: 10.1016/j.athoracsur.2007.11.039



Study design (level of evidence)

Case-controlled study



Study location

United States



Study objective

To investigate the efficacy of the PleurX catheter in palliating patients with malignant pleural effusion



Study length

5 years



Study protocol

- Monocentric, retrospective review of medical records
- Patients had indwelling tunnelled pleural catheters (PleurX) inserted



Patient population

202 patients with malignant pleural effusion



Study limitations

- Single-center study with no randomisation
- The efficacy of the PleurX catheter was not compared with any other treatment for malignant pleural effusion



Study findings

100% success rate in palliating patients' symptoms

0 complications during catheter insertion

21% of patients (at least) asked to keep their catheter in even after drainage had subsided

<2% infection rate and <5% blockage rate

4% fluid re-accumulation rate after catheter removal (n=5)

97% patient compliance with drainage schedule (n=196)

Infection was less common in patients with breast and gynaecological cancer compared with other cancers

Catheter indwelling time >100 days was most common in patients with trapped lung (p=0.001)



Key points

Extremely high patient compliance with drainage schedule and acceptance of the PleurX catheter

The PleurX catheter provided comfort and long-term control of malignant pleural effusion, with few complications

The PleurX catheter enables outpatient management of malignant pleural effusion, unlike many alternatives

60% catheter removal with very low rate of fluid re-accumulation, even in patients with trapped lung



Study conclusion

PleurX catheters effectively palliate patients with malignant pleural effusion on an outpatient basis with high compliance and favourability among patients

Phase III intergroup study of talc poudrage vs talc slurry sclerosis for malignant pleural effusion



Study author(s)

Carolyn M. Dresler, Jemi Olak,
James E. Herndon, *et al.*



Publication

CHEST 2005
DOI: 10.1378/chest.127.3.909



Study design (level of evidence)

Randomised control trial



Study location

France



Study objective

To demonstrate the efficacy, safety and appropriate delivery method of talc for sclerosis in treating malignant pleural effusion



Study length

4 years



Study protocol

- Prospective, randomised trial
- Patients received either talc poudrage (insufflation) or talc slurry
- Primary endpoint: percentage of patients whose lung initially re-expanded >90% and who had a successful pleurodesis at 30 days after treatment
- Secondary endpoints: time to effusion recurrence, complications and toxicity frequency, and lung re-expansion ability



Patient population

501 patients with malignant pleural effusion



Study limitations

- Previous studies had a smaller sample size and often defined effusion 'recurrence' differently
- Variable follow-up period
- Further work is needed to define the aetiology and risk of respiratory failure due to talc instillation



Study findings

78% success rate using talc insufflation

71% success rate using talc slurry

Talc insufflation was significantly more successful than talc slurry in patients with >90% lung re-expansion before treatment (67% vs 56%; $p=0.045$)

4% treatment-related death rate for both talc insufflation and slurry

No significant difference in talc delivery efficiency between talc insufflation and talc slurry among all treated patients ($p=0.169$)

Patients who had talc insufflation more commonly experienced respiratory complications and failure ($p=0.007$)

Insufflation gave more comfort ($p=0.019$), medical safety ($p=0.013$), and pain relief ($p=0.07$) than slurry

Groups had similar time for recurrence of effusion



Key points

Pleurodesis rates for talc insufflation and slurry are lower than previously reported trials

Causes of treatment-related death and severe respiratory complications were unpredictable

Similar 30-day success rates between talc delivery methods

Talc slurry is simpler, less invasive and lower risk than talc insufflation



Study conclusions

Efficacy for both talc insufflation and talc slurry were lower than previously reported

For patients with lung or breast cancer, talc insufflation was better than talc slurry at preventing recurrence of malignant pleural effusion

Talc pleurodesis through indwelling pleural catheters for malignant pleural effusions: retrospective case series of a novel clinical pathway



Study author(s)

Liju Ahmed, Hugh Ip Deepak Rao, Nishil Patel and Farinaz Noorzad



Publication

CHEST 2014
DOI: 10.1378/chest.14-0394



Study design (level of evidence)

Case-controlled study



Study location

United Kingdom



Study objective

To examine safety and efficacy data of patients with malignant pleural effusion undergoing talc pleurodesis through the PleurX catheter



Study length

2 years



Study protocol

Monocentric, retrospective review of safety and efficacy from patient records



Patient population

24 patients with a malignant pleural effusion



Study limitations

- Monocentric study with a small sample size and no control group
- No objective records of symptom improvement because of retrospective study design
- Inconsistent timings of pleurodesis assessment
- Results need to be confirmed in a multicentric study



Study findings

92% of patients achieved successful pleurodesis (n=22)

92% of patients had the catheter inserted on an outpatient basis (n=22) and **100%** of these patients were successfully discharged the same day

21% overall complications rate (n=5)

13% major complications rate (n=3)

– Major complications: hydropneumothorax, empyema and recurrent effusion



Key points

The PleurX catheter allows long-term drainage for patients with trapped lung, where talc pleurodesis usually fails

Complications with the PleurX catheter were rare, with no blockages following talc instillation

Giving talc slurry through the PleurX catheter is safe and effective in an outpatient setting

PleurX catheter insertion requires no hospital admission



Study conclusion

Unlike most chest drain procedures, talc pleurodesis through the PleurX catheter enables safe and effective management of malignant pleural effusion in an outpatient setting

Indwelling tunneled pleural catheters for management of hepatic hydrothorax.

A pilot study



Study author(s)

Alexander Chen, Jennifer Massoni, Diana Jung and Jeffery Crippin



Publication

Ann Am Thorac Soc 2016
DOI: 10.1513/AnnalsATS.201510-688BC



Study design (level of evidence)

Cohort study



Study location

United States



Study objective

To evaluate the feasibility of using the indwelling tunnelled pleural catheter to manage hepatic hydrothorax



Study length

6 weeks



Study protocol

- Monocentric, prospective feasibility study
- Patients had indwelling tunnelled pleural catheters (PleurX) inserted



Patient population

24 patients who were candidates for liver transplantation



Study limitations

- Small sample size as hepatic hydrothorax among patients with cirrhosis is rare



Study findings



33% of patients (n=8) achieved spontaneous pleurodesis with no fluid re-accumulation, in a mean time of 132 days

100% of PleurX catheters were successfully removed without re-accumulation of pleural fluid

0 patients required further drainage procedures after removal

17% (n=4) had pleural fluid infection

- 3 patients needed their catheter removed because of pleural fluid infection
- No patients had catheter-site cellulitis



Key points

Indwelling pleural catheters successfully controlled the symptoms of hepatic hydrothorax in patients awaiting liver transplantation

Similar spontaneous pleurodesis rates in catheters inserted for hepatic hydrothorax and malignant pleural effusion, but infection rate may be higher



Study conclusion

The PleurX indwelling tunnelled pleural catheter may be successfully and safely used in patients with benign pleural effusion to control hepatic hydrothorax

Management of malignant pleural effusion: a cost-utility analysis



Study author(s)

Majid Shafiq, Kevin D. Frick, Hans Lee, *et al.*



Publication

J Broncho Interv Pulmonol 2015

DOI: 10.1097/LBR.0000000000000192



Study design (level of evidence)

Systematic review



Study location

United States



Study objective

To perform a cost–utility analysis of different interventions for managing malignant pleural effusion



Study length

Not applicable



Study protocol

- A cost–utility analysis combining current published findings with data from the US Federal Health insurance Program (Medicare)
- Incremental cost-effectiveness ratios were determined over 6 months for five interventions: tunnelled pleural catheters, repeated thoracentesis, talc slurry, talc poudrage and rapid pleurodesis protocol



Patient population

Adults with malignant pleural effusion and had undergone therapeutic thoracentesis



Study limitations

- This model assumes patients are being treated in an outpatient setting
- The analysis is based on population averages, and so may not apply to individual patients



Study findings

A tunnelled pleural catheter had an incremental cost-effectiveness ratio of **\$45,747** per quality-adjusted life-year over repeated thoracentesis

Repeated thoracentesis was the least effective intervention

Rapid pleurodesis protocol was not cost-effective

Talc pleurodesis was the most expensive intervention, but was no more effective



Key points

The tunnelled pleural catheter is the most cost-effective treatment for malignant pleural effusion



Study conclusions

The tunnelled pleural catheter is the most cost-effective and convenient procedure in patients with malignant pleural effusion

The tunnelled pleural catheter is the intervention of choice for patients with malignant pleural effusion and an expected survival of around 6 months

Prospective evaluation of the PleurX catheter when used to treat recurrent ascites associated with malignancy



Study author(s)

Angi Courtney, Albert A Nemcek Jr, Stefanie Rosenberg, *et al.*



Publication

J Vasc Interv Radiol 2008
DOI: 10.1016/j.jvir.2008.09.002



Study design (level of evidence)

Cohort study



Study location

United States



Study objective

To assess safety and quality of life (QoL) outcomes with the PleurX catheter when managing recurrent ascites in patients with advanced abdominal ascites



Study length

1 year



Study protocol

- Multicentric, prospective study
- Patients underwent drainage sessions with the PleurX catheter
- Assessed QoL using the Memorial Symptom Assessment Survey and Subjective Significance Questionnaire



Patient population

34 patients with non-hepatic abdominal ascites



Study limitations

- Small sample size
- Limited ascites-specific instruments for measuring QoL
- The study excluded subjects with cirrhosis, so cannot be generalised to all patients with malignant ascites



Study findings

100% success rate for catheter insertions without procedural complications

85% of patients experienced no catheter failures (n=29)



Significantly reduced bloating and abdominal discomfort from baseline in patients at 2 and 8 weeks ($p < 0.05$)

83–100% of patients said their ascites was well controlled each week

No procedure-related deaths

56% of patients reported improved QoL 1 week after insertion

15% of patients experienced catheter failure (n=5), of which 9% of patients (n=3) had interventions

The most common adverse event was ascites leakage (21%), but the leak reduced as the tunnel matured



Key points

The PleurX catheter successfully treats recurrent malignant ascites without significant rates of complication, failure or discomfort

The PleurX catheter relieves symptoms and improves QoL for patients with end-stage malignancy

The catheter offers an alternative to percutaneous peritoneal venous shunting



Study conclusions

The PleurX catheter relieves malignant ascites-related discomfort and symptoms

The PleurX catheter has low rates of serious adverse clinical events and catheter failure

Tunneled peritoneal drainage catheter placement for refractory ascites: single-center experience in 188 patients



Study author(s)

Matthew P. Lungren, Charles Y. Kim,
Jessica K. Stewart, *et al.*



Publication

J Vasc Interv Radiol 2013
DOI: 10.1016/j.jvir.2013.05.042



Study design (level of evidence)

Case-controlled study



Study location

United States



Study objectives

To assess the safety and success of the PleurX catheter for managing refractory ascites



Study length

6.5 years



Study protocol

- Large, monocentric, retrospective review of medical records
- Patients had tunnelled peritoneal drainage catheters (PleurX) inserted



Patient population

188 consecutive patients with refractory ascites



Study limitations

- This study is a retrospective analysis of a relatively small patient population
- The catheter survival days may have been underestimated in 6% of patients whose death could not be determined
- No standardised grading to determine quality of life improvement



Study findings

100% success rate for catheter insertions

Patients had the catheter inserted for up to **796 days** (~2 years, 2 months)

0.3 complications per year

7.3% of catheter insertions had complications

No procedure-related deaths or major complications occurred

60 days mean catheter survival

Pancreatic cancer predicted catheter malfunction ($p=0.007$)



Key points

The PleurX catheter successfully managed refractory ascites

The PleurX catheter had very low rates of catheter malfunction (2.5%)

Cellulitis and peritonitis was rare among patients



Study conclusion

Patients with refractory ascites who were treated with the PleurX peritoneal catheter underwent successful insertion and had few complications

PleurX peritoneal catheter drainage system for vacuum-assisted drainage of treatment-resistant, recurrent malignant ascites: a NICE Medical Technology Guidance



Study author(s)

Judith White and Grace Carolan-Rees



Publication

Appl Health Econ Health Policy 2012

DOI: 10.2165/11634720-000000000-00000



Study design (level of evidence)

Guideline



Study location

United Kingdom



Study objective

To compare the cost-effectiveness of the indwelling PleurX peritoneal catheter drainage system with large-volume paracentesis in patients with treatment-resistant, recurrent malignant ascites



Study length

Not applicable



Methodology (cost analysis)

- Evaluated costs per patient
- Compared costs and patient impact of catheter use in the community setting with that of inpatient and outpatient large-volume paracentesis



Patient population

Patients with treatment-resistant, recurrent malignant ascites



Study limitations

- This evidence is based on observational studies, and there is currently very limited data available comparing the PleurX peritoneal catheter drainage system with other interventions



Study findings

The PleurX peritoneal catheter and drainage system is more cost effective than inpatient large-volume paracentesis:

- Estimated cost per patient for PleurX is £2,466 compared with £3,146 for inpatient large-volume paracentesis and £1,457 for outpatient large-volume paracentesis
- PleurX peritoneal catheter saves around

£679 per patient compared with inpatient large-volume paracentesis

- Cost savings associated with the PleurX peritoneal catheter drainage system depend heavily on reducing hospital stay



NICE recommendations

The PleurX peritoneal catheter drainage system should be considered for patients with treatment-resistant, recurrent malignant ascites

Enables early and frequent treatment in the community, reducing treatment waiting times

The clinical evidence suggests that the PleurX peritoneal catheter drainage system:


- is clinically effective with a low complication rate
- could improve quality of life
- enables early and frequent treatment in the community, reducing treatment waiting times



Study conclusions

NICE concluded that the PleurX peritoneal catheter drainage system may improve quality of life, and is a clinically safe and effective palliative therapy for treatment-resistant, recurrent malignant ascites

Switching from inpatient large-volume paracentesis to the PleurX peritoneal catheter saves around £679



 CareFusion
75 North Fairway Drive
Vernon Hills IL 60061 USA

 CareFusion France 309 S.A.S.
8 bis rue de la Renaissance
44110 Châteaubriant France

Swiss Headquarters:

BD Switzerland Sàrl
Terre Bonne Park - A4
Route de Crassier 17
1262 Eysins
Switzerland

bd.com

Refer to the complete instructions for use accompanying the devices or follow the instructions on the product labeling.
Medical devices class I sterile, IIa and IIb, according to Medical devices Council Directive 93/42/EEC, CE marked by TÜV
SÜD Product Service GmbH (0123).
© 2017 BD. BD, the BD Logo and PleurX are trademarks of Becton, Dickinson and Company. CF03451 issue 1 Sept 2017.

